daunorubicin + idarubicin + silibinin

daunorubicin + idarubicin + silibinin is a combination regimen consisting of two anthracycline chemotherapeutic agents, daunorubicin (daunomycin) and idarubicin, along with the flavonolignan silibinin (silybinin). Daunorubicin and idarubicin are potent antineoplastic agents that exert their effects by intercalating into DNA and inhibiting the enzyme topoisomerase II, which leads to the inhibition of DNA synthesis and the induction of apoptosis in rapidly dividing cells, such as those in acute myeloid leukemia (AML). Silibinin, derived from milk thistle, is included in this regimen primarily for its hepatoprotective properties; it is known to stabilize hepatocyte membranes and promote cellular integrity, potentially mitigating the liver toxicity often associated with intensive chemotherapy. Additionally, silibinin has demonstrated preclinical activity in inhibiting the growth and differentiation of various cancer cell lines. This combination is being investigated by Fujian Medical University Union Hospital for the treatment of newly diagnosed non-M3 acute myeloid leukemia.

Other names

daunomycin + idarubicin + silybinindaunorubicin + idarubicin + silibinin